Jefferies analyst David Windley maintained a Buy rating on IQVIA Holdings (IQV – Research Report) on July 11 and set a price target of $255.00. The company’s shares closed last Thursday at $209.11, close to its 52-week low of $194.67.
According to TipRanks.com, Windley is a top 100 analyst with an average return of 15.3% and a 68.9% success rate. Windley covers the Healthcare sector, focusing on stocks such as West Pharmaceutical Services, Molina Healthcare, and Elevance Health.
Currently, the analyst consensus on IQVIA Holdings is a Strong Buy with an average price target of $259.36, representing a 24.1% upside. In a report issued on July 7, Robert W. Baird also maintained a Buy rating on the stock with a $260.00 price target.
IQVIA Holdings’ market cap is currently $40.09B and has a P/E ratio of 38.19.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
North Carolina-based IQVIA Holdings, Inc. provides advanced analytics, technology solutions, and contract research services to the life sciences industry. The company operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.
Read More on IQV: